About anifrolum ab
Type I interferon receptor antagonist
Used for
- Add-on treatment for adults with moderate-to-severe systemic lupus erythematosus receiving standard therapy.
Usual adult dose
300 mg by intravenous infusion over 30 minutes every 4 weeks.
Common side effects
- Upper respiratory infections
- Bronchitis
- Infusion-related reactions
- Shingles
Important warnings
- Serious infections can occur; avoid starting during an active infection.
- Avoid live vaccines during treatment.
- Not recommended for severe active lupus nephritis or severe active central nervous system lupus.
Pregnancy
Human pregnancy data are limited; use only when potential benefit justifies potential risk.
Breastfeeding
It is unknown whether anifrolumab passes into breast milk; effects on infants are uncertain.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.